{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tirzepatide&page=9",
    "query": {
      "intervention": "tirzepatide",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 178,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tirzepatide&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tirzepatide&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T10:02:32.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05433584",
      "title": "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Antihyperglycemic medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 780,
      "start_date": "2022-08-01",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-12",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Canoga Park, California • Huntington Park, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05433584"
    },
    {
      "nct_id": "NCT07803744",
      "title": "A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Overweight",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2026-09-11",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07803744"
    },
    {
      "nct_id": "NCT05412004",
      "title": "Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstructive Sleep Apnea",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 469,
      "start_date": "2022-06-21",
      "completion_date": "2024-03-29",
      "has_results": true,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 18,
      "location_summary": "Riverside, California • Brandon, Florida • Ocala, Florida + 15 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05412004"
    },
    {
      "nct_id": "NCT06721507",
      "title": "2024 Tirzepatide-Bariatric Surgery",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity and Obesity-related Medical Conditions",
        "Bariatric Surgery"
      ],
      "interventions": [
        {
          "name": "tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Marlene Starr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-03-27",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06721507"
    },
    {
      "nct_id": "NCT05260021",
      "title": "A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type2 Diabetes",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "T2D",
        "T2DM (Type 2 Diabetes Mellitus)",
        "Glucose Metabolism Disorders",
        "Endocrine System Diseases",
        "Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Tirzepatide Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide Dose 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 99,
      "start_date": "2022-04-13",
      "completion_date": "2025-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260021"
    },
    {
      "nct_id": "NCT06643728",
      "title": "A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity",
        "Overweight"
      ],
      "interventions": [
        {
          "name": "Bimagrumab",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Bimagrumab Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 252,
      "start_date": "2024-10-21",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 12,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06643728"
    },
    {
      "nct_id": "NCT07220473",
      "title": "Tirzepatide to Slow Biological Aging",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aging",
        "LONGEVITY 1"
      ],
      "interventions": [
        {
          "name": "Zepbound",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "55 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2026-02-27",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220473"
    },
    {
      "nct_id": "NCT06732245",
      "title": "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity and Overweight"
      ],
      "interventions": [
        {
          "name": "NA-931",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "NA-931 150 mg + no Tirzepatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biomed Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 224,
      "start_date": "2026-08-15",
      "completion_date": "2027-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06732245"
    },
    {
      "nct_id": "NCT06801015",
      "title": "Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-01",
      "completion_date": "2028-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06801015"
    },
    {
      "nct_id": "NCT07756359",
      "title": "Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pouch, Ileal",
        "Pouches, Ileoanal",
        "Bowel Diseases, Inflammatory"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Loperamide",
          "type": "DRUG"
        },
        {
          "name": "Diphenoxylate/Atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-09",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-20T10:02:32.336Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Rochester, Minnesota • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07756359"
    }
  ]
}